Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GWPH GW Pharmaceuticals	$218.96	$218.59	$87.07 ▼ $219.57	$6.86B	2.15	899,771 shs	N/A
ONC Beigene	$240.41 +0.9%	$240.14	$141.31 ▼ $287.88	$23.81B	0.35	462,101 shs	189,191 shs
SMMT Summit Therapeutics	$26.04 +1.6%	$23.36	$2.30 ▼ $36.91	$19.34B	-0.94	3.81 million shs	1.99 million shs
TEVA Teva Pharmaceutical Industries	$18.13 +2.4%	$15.47	$12.47 ▼ $22.80	$20.56B	0.62	9.99 million shs	11.47 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GWPH GW Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ONC Beigene	+0.88%	+1.66%	-3.63%	-13.64%	+24,040,999,900.00%
SMMT Summit Therapeutics	+1.56%	+2.48%	+8.00%	+40.83%	+989.54%
TEVA Teva Pharmaceutical Industries	+2.31%	+9.38%	+20.63%	+11.08%	+8.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GWPH GW Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONC Beigene	2.9041 of 5 stars	4.5	0.0	0.0	0.0	1.8	1.7	0.6
SMMT Summit Therapeutics	3.0805 of 5 stars	4.5	3.0	0.0	0.0	2.6	1.7	0.0
TEVA Teva Pharmaceutical Industries	2.6156 of 5 stars	3.6	3.0	0.8	0.0	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GWPH GW Pharmaceuticals	0.00	N/A	N/A	N/A
ONC Beigene	3.00	Buy	$319.00	32.69% Upside
SMMT Summit Therapeutics	3.09	Buy	$37.40	43.63% Upside
TEVA Teva Pharmaceutical Industries	3.11	Buy	$24.50	35.14% Upside

Current Analyst Ratings Breakdown

Latest GWPH, ONC, TEVA, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	ONC Beigene	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$312.00 ➝ $311.00
5/8/2025	ONC Beigene	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$348.00 ➝ $350.00
5/8/2025	SMMT Summit Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
5/2/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $41.00
4/28/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
4/28/2025	ONC Beigene	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$312.00 ➝ $312.00
4/28/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00 ➝ $40.00
4/28/2025	TEVA Teva Pharmaceutical Industries	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GWPH GW Pharmaceuticals	$311.33M	22.05	$0.01 per share	18,588.22	$23.48 per share	9.33
ONC Beigene	$4.18B	5.70	N/A	N/A	$37.10 per share	6.48
SMMT Summit Therapeutics	$700K	27,627.18	N/A	N/A	$0.11 per share	236.73
TEVA Teva Pharmaceutical Industries	$16.62B	1.24	$3.59 per share	5.05	$4.75 per share	3.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GWPH GW Pharmaceuticals	-$9.02M	-$0.24	N/A	608.22	N/A	-11.05%	-7.46%	-6.13%	N/A
ONC Beigene	-$881.71M	-$3.72	N/A	338.61	7.73	-25.94%	-25.12%	-14.95%	N/A
SMMT Summit Therapeutics	-$614.93M	-$0.34	N/A	N/A	N/A	N/A	-85.42%	-52.66%	8/5/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.89	1.44	-9.91%	42.46%	6.65%	7/30/2025 (Estimated)

Latest GWPH, ONC, TEVA, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	ONC Beigene	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GWPH GW Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ONC Beigene	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	5.58%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GWPH GW Pharmaceuticals	0.01	5.13	4.31
ONC Beigene	0.05	1.93	1.72
SMMT Summit Therapeutics	N/A	8.31	8.31
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GWPH GW Pharmaceuticals	81.00%
ONC Beigene	48.55%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
GWPH GW Pharmaceuticals	3.10%
ONC Beigene	6.62%
SMMT Summit Therapeutics	84.90%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GWPH GW Pharmaceuticals	1,161	31.35 million	N/A	Optionable
ONC Beigene	9,000	99.05 million	90.59 million	N/A
SMMT Summit Therapeutics	110	742.67 million	86.28 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

GWPH, ONC, TEVA, and SMMT Headlines

Recent News About These Companies

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

May 28 at 12:11 PM | zacks.com

FDA fast-tracks Teva's coeliac disease treatment

May 28 at 8:33 AM | pharmaphorum.com

Capital A Wealth Management LLC Invests $596,000 in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 28 at 6:26 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408

May 27 at 9:28 PM | insidermonkey.com

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

May 27 at 5:30 PM | globenewswire.com

Teva initiated with bullish view at Truist, here's why

May 27 at 4:33 PM | https://thefly.com

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

May 27 at 4:30 PM | globenewswire.com

Why Is Teva Stock Trading Higher On Tuesday?

May 27 at 3:44 PM | benzinga.com

TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?

May 27 at 12:21 PM | zacks.com

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

May 27 at 8:30 AM | globenewswire.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 36,454 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 27 at 4:46 AM | marketbeat.com

Regulatory Shake-Up Led to the Sell Off in Teva Pharmaceutical Industries Limited (TEVA)

May 26 at 10:13 AM | finance.yahoo.com

Regulatory Shake-Up Led to the Sell Off in Teva Pharmaceutical Industries Limited (TEVA)

May 26 at 10:13 AM | insidermonkey.com

Royal Bank of Canada Increases Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 26 at 4:07 AM | marketbeat.com

Man Group plc Has $954,000 Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 26 at 3:54 AM | marketbeat.com

Two Sigma Investments LP Sells 28,694 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 25, 2025 | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Rating Increased to Buy at Wall Street Zen

May 24, 2025 | marketbeat.com

Worldquant Millennium Advisors LLC Invests $4.96 Million in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 24, 2025 | marketbeat.com

Why Investors Should Watch Teva Despite Regional Risks

May 23, 2025 | seekingalpha.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Two Sigma Advisers LP

May 23, 2025 | marketbeat.com

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

May 22, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Turbulence for Joby Shares: What's Behind the Recent Dip?
By Jeffrey Neal Johnson | May 22, 2025
View Turbulence for Joby Shares: What's Behind the Recent Dip?
3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
By Leo Miller | May 27, 2025
View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
Palantir Earnings: 1 Bullish Signal and 1 Area of Concern
By Chris Markoch | May 2, 2025
View Palantir Earnings: 1 Bullish Signal and 1 Area of Concern
Joby Just Flew Two Aircraft at Once—Here’s Why It Matters
By Jeffrey Neal Johnson | May 14, 2025
View Joby Just Flew Two Aircraft at Once—Here’s Why It Matters
Advance Auto Parts: Did Earnings Defuse Tariff Concerns?
By Gabriel Osorio-Mazilli | May 28, 2025
View Advance Auto Parts: Did Earnings Defuse Tariff Concerns?

GWPH, ONC, TEVA, and SMMT Company Descriptions

GW Pharmaceuticals NASDAQ:GWPH

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Beigene NASDAQ:ONC

$240.41 +2.10 (+0.88%)

As of 05/28/2025 04:00 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Summit Therapeutics NASDAQ:SMMT

$26.04 +0.40 (+1.56%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$26.05 +0.01 (+0.03%)

As of 06:20 AM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$18.13 +0.42 (+2.37%)

Closing price 05/28/2025 03:59 PM Eastern

Extended Trading

$18.28 +0.15 (+0.81%)

As of 06:33 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time